News
Eli Lilly (LLY) has been actively progressing its pharmaceutical offerings and forging new alliances, as recent product ...
Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...
Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.
Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...
Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.
Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...
Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...
Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate ...
A clinical trial of the drug Trontinemab will aim to delay or prevent the symptoms of Alzheimer's disease, Swiss drugmaker Roche says.
The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...
Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...
Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results